All In Biotech

Drug Trial Radar · NCT06795906

A Safety, Pharmacokinetic, and Pharmacodynamic Study of Once Daily Inhaled AZD8630 in Adults With Asthma

A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AZD8630, Administered Once Daily Via Inhalation, for 2 Weeks, in Adults With Asthma on Medium-to-high Dose Inhaled Corticosteroids and Long-acting Beta-agonists

Last checked: Nov 19, 2026Latest source record: Oct 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Jan 28, 2025

Primary completion

Jun 27, 2025

Study completion Jun 27, 2025

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Parexel
First posted
Jan 28, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomised, placebo-controlled, double-blinded, sponsor-unblinded study to assess the safety, pharmacokinetic (PK), and pharmacodynamic (PD) effect of AZD8630 in adult participants with asthma on medium-to-high dose inhaled corticosteroids (ICS) and long-acting beta-agonists (LABA).

Conditions

  • Asthma

Interventions

  • AZD8630Drug

    AZD8630 will be administered via dry powder inhalation (DPI).

  • PlaceboOther

    Placebo will be administered via DPI.

  • Saphira deviceDevice

    AZD8630 or placebo will be administered to participants via Saphira device.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of adverse events (AEs) and serious adverse events (SAEs)Time frame: From Screening (Day -28) to Follow up (Day 21)
  2. Number of adverse events leading to discontinuation (DAEs)Time frame: From Day 1 to Day 14
  3. Area under the plasma concentration curve from zero to the last quantifiable concentration (AUClast)Time frame: Day 1, Day 14 and Follow up (Day 21)
  4. Maximum observed plasma (peak) drug concentration (Cmax)Time frame: Day 1, Day 14 and Follow up (Day 21)

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Ahrensburg, Germany

  • Research Site

    Berlin, Germany

  • Research Site

    Mainz, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.